Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for ARWR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -59.06M
March 31, 2026 -31.31M
December 31, 2025 344.30M
September 30, 2025 179.55M
June 30, 2025 21.84M
March 31, 2025 56.15M
December 31, 2024 -496.28M
September 30, 2024 -462.85M
June 30, 2024 -350.89M
March 31, 2024 -256.92M
December 31, 2023 -196.21M
September 30, 2023 -153.89M
June 30, 2023 -197.30M
March 31, 2023 -244.70M
December 31, 2022 -150.30M
September 30, 2022 -136.13M
June 30, 2022 -91.58M
March 31, 2022 -52.34M
December 31, 2021 148.80M
September 30, 2021 171.22M
June 30, 2021 184.49M
March 31, 2021 180.67M
December 31, 2020 -110.78M
September 30, 2020 -95.39M
June 30, 2020 -70.73M
Date Value
March 31, 2020 -26.78M
December 31, 2019 -18.78M
September 30, 2019 173.03M
June 30, 2019 156.54M
March 31, 2019 131.61M
December 31, 2018 135.75M
September 30, 2018 -47.22M
June 30, 2018 -53.75M
March 31, 2018 -49.75M
December 31, 2017 -48.63M
September 30, 2017 -23.94M
June 30, 2017 -24.92M
March 31, 2017 -32.86M
December 31, 2016 -33.28M
September 30, 2016 -64.43M
June 30, 2016 -66.27M
March 31, 2016 -61.03M
December 31, 2015 -62.66M
September 30, 2015 -65.71M
June 30, 2015 -64.61M
March 31, 2015 -61.27M
December 31, 2014 -52.59M
September 30, 2014 -35.42M
June 30, 2014 -29.89M
March 31, 2014 -25.45M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Sarepta Therapeutics, Inc. 93.95M
Revolution Medicines, Inc. -1.223B
Moderna, Inc. -1.073B
Intellia Therapeutics, Inc. -346.64M
Denali Therapeutics, Inc. -434.04M